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Abstract
Deletion-induced hemizygosity may unmask deleterious autosomal recessive variants and be a cause of the
phenotypic variability observed in microdeletion syndromes. We performed complete exome sequencing (WES)
analysis to examine this possibility in a patient with 1p13.2 microdeletion. Since the patient displayed clinical features
suggestive of Noonan Syndrome (NS), we also used WES to rule out the presence of pathogenic variants in any of
the genes associated with the different types of NS. We concluded that the clinical findings could be attributed solely
to the 1p13.2 haploinsufficiency. Retrospective analysis of other nine reported patients with 1p13.2 microdeletions
showed that six of them also presented some characteristics of NS. In all these cases, the deleted segment included
the NRAS gene. Gain-of-function mutations of NRAS gene are causally related to NS type 6. Thus, it is conceivable
that NRAS haploinsufficiency and gain-of-function mutations may have similar clinical consequences. The same
phenomenon has been described for two other genes belonging to the Ras/MAPK pathway: MAP2K2 and SHOC2.
In conclusion, we here report genotype-phenotype correlations in patients with chromosome 1p13.2 microdeletions
and we propose that NRAS may be a critical gene for the NS characteristics in the patients.
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Introduction
Patients with chromosomal deletions may present
with variable clinical phenotypes for different reasons.
First, the deletions frequently vary in size and the pheno-
typic alterations may depend on which loci are deleted in
the specific case, as exemplified by the contiguous gene
syndromes such as, for instance, Langer-Giedion syndrome
(OMIM #150230) and Williams-Beuren syndrome (OMIM
#194050). Second, the phenotypic effect of the deleted seg-
ment may be modulated by some specific regions of the rest
of the genome, in analogy with autosomal dominant dis-
eases with variable expressivity and as, for instance, is the
case in digenic inheritance (Schaffer, 2013). Third, early
postzygotic events, and/or environmental factors may in-
fluence phenotypic discordances, such as in cases of mono-
zygotic twins with discordant phenotype and chromosome
22q11.2 microdeletion (Yamagishi et al., 1998). Fourth,
the clinical phenotype may be influenced by the presence of
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a pathogenic variant in a gene located in the region homolo-
gous to the deleted segment, in the intact member of the
chromosome pair. This phenomenon has been termed “un-
masking heterozygosity” (UH) and when it occurs the phe-
notype of a recessive disease might emerge from the
microdeletion due to hemizygosity (Coman and Gardner,
2007; Poot, 2012). To our knowledge, the earliest example
of this phenomenon was described in retinoblastoma
(OMIM #180200), which may occur because a chromo-
somal deletion may cause hemizygosity for an RB1 (OMIM
*614041) pathogenic variant on chromosome 13q14.
Next generation sequencing (NGS) techniques, such
as whole genome sequencing (WGS) and whole exome se-
quencing (WES) allow the screening of the genome includ-
ing the non-deleted allele for variants that may contribute to
variable phenotypic expression in deletion syndromes. Ac-
cordingly, NGS has been reported to reveal deleterious
variants unmasked by hemizygous deletions in individuals
with 22q11.2 deletion syndrome (OMIM #192430;
#188400) (McDonald-McGinn et al., 2013), with mental
retardation or multiple congenital abnormalities and hemi-
zygous deletions (Hochstenbach et al., 2012), and with
thrombocytopenia absent radius syndrome (OMIM
#274000) (Albers et al., 2012).
Since UH can be revealed using exome sequencing,
we used it in a genotype-phenotype correlation study of
chromosome 1p13.2 microdeletions. We here report the
case of a 21-year-old man with a multisystem phenotype
containing some features of Noonan syndrome (OMIM
#613224) and 1p13.2 deletion extending from
1:112,096,417 to 1:115,805,157 (hg19) diagnosed by
aCGH. Exome sequencing analysis examined the possibil-
ity of a recessive pathogenic variant unmasked by his hemi-
zygous deletion and also verified if he had pathogenic
variants in any of the Noonan Syndrome genes. We con-
cluded that the clinical characteristics of the patient could
be attributed to the 1p13.2 haploinsufficiency. Additio-
nally, we compared his clinical characteristics with the phe-
notype of six patients with similar deletions overlapping
the one of our patient reported previously in DECIPHER
database and three individuals reported in the literature
(Mattia et al., 1992; Bisgaard et al., 2007; Fitzgibbon et al.,
2009). On these bases we propose that haploinsufficiency
of NRAS gene (OMIM *164790) may be important in deter-
mining the clinical phenotype of this microdeletion.
Clinical report
Our patient was a 21-year-old man born of healthy
unrelated parents (DECIPHER patient no. 274660). He was
born at 37 weeks of pregnancy by cesarean delivery for
breech presentation. Birth weight was 2,720 g (3rd-10th
centile), with length of 47 cm (10th centile) and occipital
frontal circumference (OFC) 34.5 cm (25-50th centile). He
presented with hypotonia and feeding difficulties in in-
fancy. His motor development was delayed, having walked
independently at 22 months of age. At 3 years-old he spoke
single words and at 4 years-old he spoke sentences. He
never learned to write or to read. Since infancy he has had
recurring bouts of vomiting. Colonoscopy revealed a poly-
poid mucosa in the terminal ileum and chronic enteritis.
Ophthalmologic exams showed myopia, with normal
fundus. Echocardiography and nuclear magnetic resonance
of the brain were normal.
He was evaluated by a geneticist at 20 years of age,
when his weight was 68.5 kg (25-50th centile), height 161
cm (< 3rd percentile) and OFC 53 cm (< 3rd percentile).
Besides the short stature, his phenotype had several fea-
tures reminiscent of Noonan Syndrome, including intellec-
tual disability, ptosis, low hairline at the nape, broad neck,
excess of pigmented nevi resembling lentigines, pectus
excavatum and scoliosis (see Figure 1). Complementary
examinations showed patellar chondromalacia, osteoporo-
sis, asymmetry of the lower limbs, nephrolithiasis with in-
creased loss of K+ and Ca+ in urine, hypercholesterolemia
and primary hypothyroidism. The conventional karyotype
of the patient and his parents were normal. However, subse-
quent aCGH analysis (Agilent SurePrint G3 4x180K) re-
vealed a 3.71 Mb microdeletion on chromosome 1p13.2
(chr1:112,096,417–115,805,157; UCSC Genome Browser
hg19) (Figure 2).
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Figure 1 - Frontal view of patients with deleted NRAS. Patients present features of Noonan Syndrome 6, including macrocephaly, short/webbed neck, low
hairline, skin abnormalities, triangular face with age, low-set ears, arched eyebrows, hypertelorism, ptosis, downslating palpebral fissures and epicanthal
folds. Considering the patients with NRAS deletion, we did not have a picture of patient 253793 and 258063.
Material and Methods
Samples and DNA isolation
This study was approved by the Research Ethics
Committee of Universidade Federal de Minas Gerais and
by the Brazilian National Committee of Ethics in Research
(CONEP – Brazil) with number 854.709. Written informed
consent including permission for publication was provided
by the parents. Genomic DNA was isolated from peripheral
blood of the patient using a modified salting out procedure
(Miller et al., 1988).
Whole exome sequencing and analysis
Whole exome sequencing was performed in the pa-
tient sample by The Centre for Applied Genomics, The
Hospital for Sick Children (Toronto, Canada) using the
Agilent SureSelect Human All Exon V4 Kit (Agilent Tech-
nologies) and SOLiD 5500xl platform (Applied Biosys-
tems). All data were aligned to the hg19/GRCh37 reference
genome build via BFAST and BWA aligner. Variants were
quality trimmed using the Genome Analysis Toolkit
(GATK 1.1.28) and they were annotated for functional ef-
fect by SnpEff 2.0.5. SnpEff also provided a simple assess-
ment of the putative impact of the variant (e.g. High, Mode-
rate, or Low impact). Alignment, calling and annotation of
the variants against databases such as 1000 Genomes (April
2012 release), NHLBI Exome Sequencing Project
(ESP6500) and Single Nucleotide Polymorphism database
(dbSNP137) were done using a software developed in-
house called Mendel,MD (Cardenas et al., 2015). The pre-
diction software SIFT (Sorting Intolerant From Tolerant)
was used in order to estimate whether a given amino acid
substitution affected protein function. SIFT prediction is
based on the degree of conservation of amino acid residues
in sequence alignments derived from closely related se-
quences and on the physical properties of amino acids.
Results
Whole exome sequencing of the patient sample iden-
tified 76,822 variants. Approximately 26,863 of these vari-
ants passed in the GATK quality filters and had a Minor
Allele Frequency (MAF)  0.01 in the 1000 Genomes,
ESP6500 and dbSNP137. In the deleted region, which ex-
tended from 1:112,096,417 to 1:115,805,157 (hg19), exo-
me analysis revealed 35 hemizygous variants that passed in
GATK quality filters. Only 10 of these variants were con-
sidered to have moderate or high impact by SnpEff, which
means that they are assumed to have high disruptive impact
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Figure 2 - Copy number profile of chromosome 1 of our patient obtained by aCGH. The chromosome 1 copy number imbalances are indicated on the left
panel and shown in detail on the right panel: the alterations marked by the square show a ~3.71 Mb 1p13.2 deletion.
in the protein or might change protein effectiveness (exam-
ples: stop gained, frameshift, missense and splice donor
variants). Based on the assumption that the potential dam-
aging variants are rare, the variants were then filtered con-
sidering an allele frequency < 0.01 in the 1000 Genomes
database, ESP6500 and dbSNP137, however no plausibly
pathogenic variant was retained. Besides, all of these 10
variants were predicted as tolerated by SIFT (score  0.05)
(Table S1). In addition, we verified by exome analysis that
the patient did not have any pathogenic variants in the
genes associated with Noonan Syndrome and other raso-
pathies (PTPN11, SHOC2, KRAS, CBL, SOS1, RAF1,
HRAS, NRAS, RASA1, SPRED1, BRAF, MAP2K1,
MAP2K2, RIT1 and RRAS) (Rauen, 2013; Ekvall et al.,
2015).
The deleted 1p13.2 region of our patient contained 69
genes according to the NCBI Map Viewer Annotation Re-
lease 105, of which 28 were listed in OMIM (Table S2).
However, only eight of these genes were known to be asso-
ciated with Mendelian disease phenotypes (Table S3).
Among the recessive disease genes there was the TSHB
gene (OMIM *188540), in which homozygous mutations
had been reported in patients with congenital nongoitrous
hypothyroidism-4 (OMIM #275100). Our patient had
hypothyroidism, but it was not congenital.
In order to perform a genotype-phenotype correlation
study of chromosome 1p13.2 microdeletions, we compared
the clinical characteristics of our patient to those of previ-
ously described cases (Table 1 and Figure 1). Isolated chro-
mosome 1p13.2 microdeletions are not common; we could
find only three individuals reported in the literature (Mattia
et al., 1992; Bisgaard et al., 2007; Fitzgibbon et al., 2009).
Additionally, six patients with isolated deletions partially
overlapping the one of our patient had been reported previ-
ously in DECIPHER database. All these nine patients were
included in our analysis.
The deletions in the several patients ranged from 2.19
Mb to 17.93 Mb in size and eight of them included a region
extending from 115,018,964 to 115,713,872 (hg19). The
region of overlap of all patients contained 10 genes:
TRIM33, BCAS2, DENND2C, AMPD1, NRAS, CSDE1,
SIKE1, SYCP1, TSHB, TSPAN2 (Figure 3). The Database
of Genomic Variants (DGVbeta) lists numerous copy-num-
ber variations (CNVs) in individuals with normal pheno-
types within this region. The segment with the least number
of CNVs was the one containing the genes AMPD1, NRAS
and CSDE1 (Figure 4).
The patient reported by Fitzgibbon et al. (2009) pre-
sented congenital insensitivity to pain and temperature,
which led the authors to propose that this might be a conse-
quence of haploinsufficiency of the NGF gene (OMIM
*162030), which is related to hereditary sensory and auto-
nomic neuropathy type V, an autosomal recessive disease
(sequencing of the undeleted homologous chromosome had
not shown any pathogenic variants). However, in disagree-
ment with this suggestion, NGF was also deleted in three
patients described in DECIPHER, none of whom presented
congenital insensitivity to pain and temperature (patients
no. 250335, 253793 and 260230). In relation to coloboma,
Bisgaard et al. (2007) hypothesized that haploinsufficiency
of the WNT2B gene (OMIM *601968) might have caused it
in their patient. Indeed, this gene was deleted in two other
patients with ocular coloboma (Patients no. 250335 and
257066), but it was also deleted in our patient, who did not
have this malformation.
Discussion
We here report a patient with isolated 1p13.2 micro-
deletion diagnosed by aCGH analysis. We performed exo-
me sequencing in the patient in order to check for possible
unmasking heterozygosity and to exclude variants in any of
the genes related to Noonan Syndrome or other RASopa-
thies. The analysis of complete exome sequencing (WES)
identified 35 hemizygous variants in the deleted region.
However, evaluation of frequency in the population and
bioinformatics protein predictions did not indicate pathoge-
nicity of these variants. Moreover, we did not find patho-
genic variants in any of the genes known to be associated
with Noonan Syndrome. Consequently, we conclude that
the phenotype of our patient is exclusively related to his
hemizygous 1p13.2 state.
We then tried to identify in the deletion region, genes
possibly related with the phenotype of our patient and oth-
ers. Our attention was drawn to the presence of deletion of
NRAS for four reasons:
1. The phenotype of our patient and also of other pa-
tients with the 1p13.2 deletion includes several features of
Noonan Syndrome (Table 1 and Figure 1);
2. Variants of NRAS have been described as causing
Noonan Syndrome, Type 6 (OMIM #613224), an auto-
somal dominant disorder (Cirstea et al., 2010). However,
these have been shown to be gain-of-function mutations;
3. Haploinsufficiency Index predictions (HI) shown
in the DECIPHER database for all the genes deleted in our
patient, revealed that the NRAS gene was the one with
higher rank of HI (which suggested that this gene is more
likely to exhibit haploinsufficiency) (Huang et al., 2010);
4. The region surrounding NRAS is rarely seen in
polymorphic CNVs (Figure 4).
NRAS is a member of the Ras subfamily, which in-
cludes 36 members; KRAS, HRAS and NRAS have been the
most studied because of their critical roles in human onco-
genesis (Wennerberg et al., 2005). Ras proteins belong to a
class of signal-transducing GTPases, which cycle between
an active GTP-bound and an inactive GDP-bound confor-
mation. Alterations of conditions, including gene variants,
may result in stabilization of Ras proteins in their active
state leading to malignant transformation (Scheffzek et al.,
1997). Ras proteins activate several pathways, including
the Ras/mitogen activated protein kinase (MAPK) pathway
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(Wennerberg et al., 2005). This pathway plays an essential
role in regulating the cell survival, differentiation, prolifer-
ation and apoptosis, among many others (Pearson et al.,
2001).
Germline variants in genes that encode components
or regulators of the Ras/MAPK pathway have been shown
to cause developmental syndromes collectively referred to
as RASopathies. These disorders include several forms of
Noonan syndrome, including Costello syndrome (OMIM
#218040), cardio-facio-cutaneous syndrome (OMIM
#115150), and capillary malformation–arteriovenous mal-
formation syndrome (OMIM #608354) (Rauen, 2013). In
all of these cases the mutations have been shown to involve
gain-of-function, increasing activity in the Ras/MAPK
pathway. It is believed that this might be the reason why
they are clinically similar, with overlapping phenotypic
features including characteristic facial features, cardiac de-
fects, cutaneous abnormalities, neurocognitive delay and
an increased cancer risk (Tidyman and Rauen, 2009;
Rauen, 2013).
Few heterozygous mutations have been described as
cause of the Noonan type 6 (NS6) and they have all been as-
sociated with gain-of-function in NRAS (De Filippi et al.,
2009; Cirstea et al., 2010; Runtuwene et al., 2011; Denayer
et al., 2012; Kraoua et al., 2012; Ekvall et al., 2015). Cirstea
et al. (2010) expressed each mutant as yellow fluorescent
protein–NRAS fusion proteins in cells from the COS-7 line
and showed for example that NRAS substitutions p.Thr50Ile
or p.Gly60Glu resulted in enhanced phosphorylation of
MEK and ERK in the presence of serum or after epidermal
growth factor (EGF) stimulation. In addition, the authors ob-
served that the p.Gly60Glu NRAS mutant accumulated con-
stitutively in the active, GTP-bound form (Cirstea et al.,
2010). Runtuwene et al. (2011) showed that similar effects
occurs in GTP-bound in p.Ile24Asn mutants and they re-
vealed that p.Gly60Glu, p.Ile24Asn and the positive control
(p.Gly12Val) mutants also enhanced MAPK activation.
These patients with NRAS mutations often show a relatively
mild phenotype of typical Noonan features, including
hypertelorism, low-set ears, short stature, webbed neck, low
hairline, thorax deformities, motor delay/muscular hypo-
tonia and lentigenes/cafe-au-lait spots (reviewed by Kraoua
et al., 2012; Ekvall et al., 2015).
On the other hand, our patient and other cases with
pure chromosome 1p13.2 microdeletions and hemizygosity
for NRAS reviewed by us from the literature or from the
DECIPHER database all seemed to present several clinical
features of Noonan Syndrome (Table 1 and Figure 1). The
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Figure 3 - Schematic representation of the deleted segments in our patient and those previously reported with isolated 1p13.2 microdeletions. Except for
the patient described by Mattia et al. (1992), who has a microdeletion from 1p13 to 1p22.3, all other patients have their breakpoints defined by molecular
methods. Ideogram of chromosome 1, physical map and deleted segments are indicated according to their placement on the Ensembl Genome Browser.
presence of such features related to Noonan Syndrome in pa-
tients with deletion of NRAS and presumably haplo-
insufficiency of the gene product appears prima facie
paradoxical.
We searched the literature and we have found three
similar examples. In Noonan syndrome, Edwards et al.
(2014) described a 5-year-old male with two de novo patho-
genic PTPN11 variants in cis (OMIM *176876). The dou-
ble-mutant gene product (SHP-2) was found to be catalyti-
cally impaired. More recently, Chen et al. (2014) described
a patient with a Noonan-like phenotype associated with a
deletion of the 10q25.2 chromosomal region that included
the SHOC2 gene (OMIM *602775). Gain-of-function mu-
tations in this gene have been shown to cause a Noonan
Syndrome-like syndrome. In the same vein, Nowaczyk et
al. (2014) reported seven patients with deletions of chro-
mosome 19p13.3 including the MAP2K2 gene (OMIM
*601263) and phenotype features of Cardio-facio-cuta-
neous syndrome, which is a RASopathy known to be cau-
sed by activating mutations of the BRAF, MAP2K1,
MAP2K2, or KRAS genes. On these bases, these authors
proposed that haploinsufficiency of MAP2K2/MEK2 “ap-
pears to be a new model of a RASopathy, where a deletion
of one of the components of the pathway, MEK2, results in
a RASopathy-like phenotype” (Nowaczyk et al., 2014). We
believe that the association here described of 1p13.2 micro-
deletion involving hemizygosity for NRAS and clinical fea-
tures of Noonan syndrome, represent a further example of
the model proposed by Nowaczyk et al. (2014), according
to which, haploinsufficiency of a gene in the Ras/MAPK
pathway may cause dysregulation of the pathway and pro-
duce a RASopathy phenotype.
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